Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Eli Lilly stock in Canada
Learn how to buy Eli Lilly stock in 5 easy steps.
Eli Lilly is a drug manufacturers-general business based in the US. Eli Lilly stocks (LLY.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $427.24 – an increase of 0.35% over the previous week. Eli Lilly employs 39,000 staff and has a trailing 12-month revenue of around $27.7 billion.
How to buy Eli Lilly stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – LLY. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
National Bank Direct Brokerage
- Commission-free trading
- Several account types available
- Access to array of research tools
CIBC Investor's Edge
- Easy to use platform
- Low fees
- Student and young investor discounts
- Access to international stock exchanges
- Low margin rates
- Powerful research tools
What's in this guide?
- Can I buy shares in Eli Lilly?
- Has coronavirus impacted Eli Lilly shares?
- Eli Lilly shares summary
- Compare share dealing platforms
- Is Eli Lilly stock a buy or sell?
- Eli Lilly performance over time
- Is Eli Lilly suitable for ethical investing?
- Are Eli Lilly shares over-valued?
- Eli Lilly's financials
- How volatile are Eli Lilly shares?
- Does Eli Lilly pay a dividend?
- Have Eli Lilly shares ever split?
- Other common questions
Eli Lilly stock price (NYSE:LLY)Use our graph to track the performance of LLY stocks over time.
Eli Lilly shares at a glance
|Latest market close||$427.24|
|52-week range||$279.80 - $454.95|
|50-day moving average||$387.29|
|200-day moving average||$350.87|
|Wall St. target price||$428.61|
|Dividend yield||$4.07 (1.06%)|
|Earnings per share (TTM)||$6.26|
Buy Eli Lilly and Company stocks from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Eli Lilly stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Eli Lilly price performance over time
Historical closes compared with the close of $427.24 from 2023-05-30
|1 week (2023-05-24)||0.35%|
|1 month (2023-05-01)||5.28%|
|3 months (2023-03-03)||34.17%|
|6 months (2022-12-01)||15.37%|
|1 year (2022-05-31)||36.31%|
|2 years (2021-05-28)||113.90%|
|3 years (2020-05-29)||179.33%|
|5 years (2018-05-31)||402.40%|
Is Eli Lilly stock undervalued or overvalued?
Valuing Eli Lilly stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Eli Lilly's P/E ratio
Eli Lilly's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 68x. In other words, Eli Lilly shares trade at around 68x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Eli Lilly's PEG ratio
Eli Lilly's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1814. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Eli Lilly's EBITDA
Eli Lilly's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.2 billion.
The EBITDA is a measure of a Eli Lilly's overall financial performance and is widely used to measure a its profitability.
Eli Lilly financials
|Revenue TTM||$27.7 billion|
|Operating margin TTM||27.82%|
|Gross profit TTM||$21.9 billion|
|Return on assets TTM||9.62%|
|Return on equity TTM||54.79%|
|Market capitalisation||$405.6 billion|
TTM: trailing 12 months
Eli Lilly's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Eli Lilly's total ESG risk score
Total ESG risk: 32.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly's overall score of 32.36 (as at 01/01/2019) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Eli Lilly's environmental score
Environmental score: 0.63/100
Eli Lilly's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Eli Lilly's social score
Social score: 16.68/100
Eli Lilly's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Eli Lilly's governance score
Governance score: 13.31/100
Eli Lilly's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Eli Lilly's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly hasn't always managed to keep its nose clean.
Eli Lilly share dividends
Dividend payout ratio: 60.81% of net profits
Recently Eli Lilly has paid out, on average, around 60.81% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.06% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly shareholders could enjoy a 1.06% return on their shares, in the form of dividend payments. In Eli Lilly's case, that would currently equate to about $4.07 per share.
Eli Lilly's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Eli Lilly's most recent dividend payout was on 9 June 2023. The latest dividend was paid out to all shareholders who bought their shares by 12 May 2023 (the "ex-dividend date").
Have Eli Lilly's shares ever split?
Eli Lilly's shares were split on a 2:1 basis on 16 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly shares which in turn could have impacted Eli Lilly's share price.
Eli Lilly share price volatility
Over the last 12 months, Eli Lilly's shares have ranged in value from as little as $279.8033 up to $454.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly's is 0.367. This would suggest that Eli Lilly's shares are less volatile than average (for this exchange).
Eli Lilly overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.
Stocks similar to Eli Lilly
Eli Lilly in the news
Ozempic: How the Diabetes Drug Works and Why It’s Such a Big Deal for Weight Loss
Lilly ESG Report Highlights Progress Towards Sustainability Goals
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
How do ETFs work?
Your guide to how ETFs work and whether this type of investment is right for you.Read more…
Best stock app for beginners for 2023
The best stock trading app for beginners is easy to use and offers free trades.Read more…
How to read stock charts
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.Read more…
More guides on Finder
Best bad credit loans in Prince Edward Island
Compare some of the best bad credit loans in PEI.
Your guide to the features, interest rates and fees to expect when you apply for a short-term loan with Credito.
5 apps like Bree in Canada
Pay for unexpected bills and avoid overdrafts when you sign up for apps like Bree.
Debt Relief Canada (reliefcanada.ca) review
Take a closer look at the debt relief solutions, features and fees of Debt Relief Canada.
Desjardins Online Brokerage (Disnat) review 2023
Learn more about Desjardins Online Brokerage (Disnat) to see if it’s the right broker for you.
Guide to finding the best prepaid card in Canada in May 2023
We show you the best prepaid credit cards in Canada, whether you’re looking for a prepaid card with no fees, cash back rewards, or travel perks, or more.
How to buy Sui (SUI) in Canada
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
5 apps like Nyble in Canada
Compare apps like Nyble in Canada to access emergency funding.
Your guide to buying and financing a car in Canada with RightRide.
Compare bad credit car loans in BC
Your guide to bad credit car loans in BC and how to find the right financing for your needs.